[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroesophageal-reflux\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroesophageal-reflux":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,42,75,99,129,155,177,201,224,259,287,315,337,365,386,408],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100557149","transpyloric-versus-gastric-feeding-in-bronchopulmonary-dysplasia-100557149",false,"NCT06534359","Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia","Pilot Trial Comparing Transpyloric to Gastric Feeding in Very Preterm Infants With Bronchopulmonary Dysplasia","Inclusion Criteria:\n\n1. Birth \\\u003C32 weeks' gestation\n2. Current postmenstrual age of 36-65 weeks\n3. Grade 2-3 bronchopulmonary dysplasia (BPD: treatment with positive airway pressure at 36 weeks' PMA) or grade 1 BPD (treatment with ≤2L\u002Fmin flow nasal cannular at 36 weeks' PMA) with subsequent need for prolonged positive airway pressure and full enteral tube feedings\n4. Treatment with positive airway pressure (high flow nasal cannula, non-invasive positive airway pressure, or invasive ventilation) at enrollment\n\n(4) Full gastric tube feedings (≥100mL\u002Fkg\u002Fd) at the time of enrollment (5) Parental consent to participate\n\nNote: At least 20 infants receiving invasive ventilation will be enrolled to enable endotracheal biomarker testing.\n\nExclusion Criteria:\n\n1. Transpyloric feedings received within 7d of enrollment\n2. Use of a gastric acid suppression, GI promotility drug, or caffeine within 7d of enrollment\n3. History of gastrostomy tube placement, gastric fundoplication, or bowel resection resulting in short gut with contraindication to transpyloric feeding\n4. Plan to wean off positive airway pressure (for non-intubated subjects) or to be extubated to non-invasive support (for subjects receiving invasive ventilation) within the 2wk trial\n5. Known intolerance to transpyloric feeding\n6. Persistent \\>20% endotracheal tube leak (for intubated subjects only)\n7. Active treatment with an investigational therapy as part of another interventional trial\n8. severe congenital or genetic abnormality that adversely affects GI or cardiopulmonary function","ALL","1 Month","12 Months",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if transpyloric tube feeding (feeding directly into the small intestine) versus gastric tube feeding tolerably and effectively reduces gastroesophageal reflux in infants born premature who have been diagnosed with bronchopulmonary dysplasia. The main questions this trial aims to answer are:\n\nDoes transpyloric as compared to gastric tube feeding result in differences in the amount of experienced hypoxemia (low oxygen level in the blood) or serious adverse events?\n\nDoes transpyloric as compared to gastric tube feeding reduce the frequency and severity of gastroesophageal reflux (GER) measured using 24 hour esophageal pH-multichannel intraluminal impedance (pH-MII) monitoring?\n\nParticipants will:\n\nUndergo pre-trial 24 hour pH-MII monitoring to determine baseline severity of GER.\n\nBe randomly assigned to receive transpyloric or gastric tube feeding for 2 weeks.\n\nUndergo repeat pH-MII at the end of the 2 week trial to assess for change in GER.\n\nUndergo continuous pulse oximetry to record level of hypoxemia during the 2 week trial.\n\nUndergo saliva and airway (if supported by a breathing tube) fluid collection to measure biomarkers of GER.\n\nBe monitored clinically for possible adverse events.",[27,28],"Bronchopulmonary Dysplasia","Gastroesophageal Reflux","RECRUITING","2026-06-26",{"date":32,"type":33},"2026-06-30","ACTUAL",{"date":35,"type":33},"2025-07-15",{"date":37,"type":21},"2027-06-30",{"name":39,"class":40},"Children's Hospital of Philadelphia","OTHER",4,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100641615","antireflux-surgery-without-preoperative-esophageal-manometry-100641615","NCT07659080","Antireflux Surgery Without Preoperative Esophageal Manometry","Laparoscopic Toupet Fundoplication With or Without Preoperative Esophageal Manometry in Patients With GERD and Hiatal Hernia","NOMA","Inclusion Criteria\n\n1. Age ≥ 18 years\n2. Documented GERD and\u002For hiatal hernia (Type I, II, or small Type III) confirmed on EGD and\u002For imaging (i.e. CT scan or upper GI study) within 12 months\n3. Presence of at least one guideline-based indication for antireflux surgery:\n\n   1. Typical GERD symptoms (heartburn and\u002For regurgitation) refractory to or recurrent after adequate PPI therapy\n   2. PPI-dependent GERD with patient preference for surgical management\n   3. Extra-esophageal GERD symptoms (chronic cough, laryngitis, asthma) with pathologic reflux confirmed on ambulatory pH study\n   4. Symptomatic Type II\u002FIII paraesophageal hernia (postprandial pain, early satiety, dysphagia to solids)\n   5. Objective documentation of pathologic esophageal acid exposure on ambulatory reflux monitoring (24-hour pH-impedance or 48-hour Bravo pH capsule) confirming GERD diagnosis, performed within 12 months of enrollment\n4. Mellow-Pinkas dysphagia score = 0 at baseline (no overt dysphagia)\n5. Eckardt score \\\u003C 1 (achalasia screening)\n6. Ability to provide informed consent and comply with 12-month follow-up.\n\nExclusion Criteria:\n\n1. Overt dysphagia (Mellow-Pinkas ≥ 1 or Eckardt ≥ 1)\n2. Prior esophageal or gastric surgery\n3. Known or clinically suspected achalasia or primary motility disorder\n4. Endoscopic stricture, mass, or luminal obstruction\n5. Giant paraesophageal hernia (Type IV, or Type III with \\>50% of stomach herniated intrathoracically)\n6. Connective tissue disease with esophageal involvement (e.g., scleroderma\u002FCREST)\n7. Active esophageal or gastric malignancy\n8. Pregnancy\n9. BMI \\> 40 kg\u002Fm² (patients with severe obesity who would be candidates for bariatric surgery should be referred for metabolic\u002Fbariatric evaluation, as per the multi-society GERD guideline recommending weight-loss surgery consideration in this population)\n10. Participation in another interventional trial within 30 days\n11. Prior esophageal manometry within 12 months demonstrating a major motility disorder (achalasia, absent contractility, distal esophageal spasm, hypercontractile esophagus); such patients should be managed per standard motility disorder pathways and are not candidates for this trial.","18 Years",{"count":52,"type":21},96,[24],"The goal of this clinical trial is to learn if people can safely skip a test called esophageal manometry before surgery for acid reflux (gastroesophageal reflux disease, or GERD) or a hiatal hernia. Manometry measures the muscles of the food pipe using a thin tube passed through the nose. The test can be uncomfortable and can delay surgery. The main questions this study aims to answer are whether people can skip manometry and still have good swallowing one year after surgery, and whether skipping the test lowers discomfort, shortens the wait for surgery, and lowers cost. To answer this, researchers will compare two groups. One group will have surgery without manometry. The other group will have manometry first, the way it is usually done. Everyone will get the same operation, a partial wrap called a Toupet fundoplication, so the study tests the value of the test and not the surgery. Participants will be placed by chance into one of the two groups, have the same standard operation, and fill out short questionnaires about their swallowing before surgery and again at 3, 6, and 12 months after surgery. Researchers want to find out if skipping manometry works just as well as the usual approach for people who do not have trouble swallowing before surgery.",[56,57,58,59,28],"GERD","Hiatal Hernia","Heartburn","Paraesophageal Hernia",[56,61,62,63,59],"hiatal hernia","fundoplication","Gastroesophageal Reflux Disease","NOT_YET_RECRUITING","2026-06-16",{"date":67,"type":33},"2026-06-22",{"date":69,"type":21},"2026-10-01",{"date":71,"type":21},"2028-04-30",{"name":73,"class":40},"McMaster University",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100449464","high-resolution-manometry-after-partial-fundoplication-for-gastro-oesophageal-reflux-100449464","NCT05132816","High Resolution Manometry After Partial Fundoplication for Gastro-oesophageal Reflux","High Resolution Manometry After Partial Fundoplication for Gastro-oesophageal Reflux: Does the Ineffective Preoperative Oesophageal Motility Change Postoperatively?","Inclusion Criteria:\n\n* Age older than 18 years\n* Ineffective esophageal motility disorder according the Chicago classification (7), defined as ≥ 7\u002F10 (70%) of swallows with weak contraction (distal contraction interval (DCI) between 100mmHg\u002Fs\u002Fcm and less than 450 mmHg\u002Fs\u002Fcm) or ≥ 5\u002F10 (50%) of swallows with failed peristalsis (DCI \\\u003C100mgHg\u002Fs\u002Fcm)Performance of partial fundoplication (180° anterior or 270° posterior) at Spital Limmattal\n* Informed Consent as documented by signature\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy\n* Normal preoperative esophageal motility\n* Other specifically defined esophageal motility disorders such as Nutcracker or Jackhammer esophagus\n* Preoperative presence of a hiatal hernia with migration of \\>20% of stomach in the chest\n* Revisional surgery (after other procedures for reflux or at the hiatus)",{"count":83,"type":21},100,[24],"This is a combined retro- and prospective, monocentric study. All patients who underwent or are planned for laparoscopic partial fundoplication (180° anterior or 270° posterior) between 2020-2023 are assessed for preoperative ineffective esophageal motility (IEM).\n\nThe main hypothesis is, that preoperative oesophageal motility disorders, especially hypo-contractility or failed peristalsis, are caused by gastro-oesophageal reflux. Therefore, postoperative manometry after partial wrap fundoplication (270° posterior, 180° anterior) shows a decrease in comparison to preoperative motility disorders.\n\nThe primary objective of this study is to examine the postoperative esophageal motility in patients with known preoperative motility disorders.\n\nSecondary endpoints are the presence of other oesophageal motility disorders pre- vs. postoperatively (including new onset disorders), the assessment of the Gastrointestinal Symptom Rating Scale (GSRS) pre- vs. postoperatively, and more.\n\nIf IEM is present preoperatively, patients are contacted at least 1 year after surgery and will be informed about the study and asked to participate. In case of agreement, they are invited to the study site. They undergo high-resolution manometry 18-24 months postoperatively (study intervention).",[28,87,88],"Esophageal Motility Disorders","Upper Gastrointestinal Disorder","2026-06-08",{"date":91,"type":33},"2026-06-09",{"date":93,"type":33},"2022-01-24",{"date":95,"type":21},"2027-12-31",{"name":97,"class":40},"Prof Urs Zingg",1,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":74},"100615368","study-on-hydrotalcite-for-relief-of-acid-symptoms-due-to-acid-rebound-after-stopping-long-term-ppi-therapy-100615368","NCT07291700","Study on Hydrotalcite for Relief of Acid Symptoms Due to Acid Rebound After Stopping Long-Term PPI Therapy","A Non-Interventional Study to Investigate the Effectiveness of Hydrotalcite to Relieve Acid-Related Symptoms Due to an Acid Rebound After Discontinuation of a Non\u002FNo Longer Indicated Long-Term PPI Therapy.","Eligibility Criteria:\n\nAdult female or male subjects aged ≥ 18\n\n* Subjects who have discontinued daily PPI therapy (≥ 8 weeks of therapy) for which there is no current indication according to guidelines and approval status, e.g.\n\n  * irritable bowel syndrome\n  * subjects who receive Non-Steroidal Anti-Inflammatory drug (NSAID) treatment with no warning signals\\* regarding ulcers\n  * polymedication\\*\\* with no warning signals\\* or side effects regarding ulcers\n  * unclarified upper abdominal discomfort\n  * mild forms of GERD; like Non-Erosive Reflux Disease (NERD), Los Angeles (LA) grade A\u002FB esophagitis\n* Suffer from acid-rebound due to a discontinuation of a non\u002Fno longer indicated long-term PPI therapy (≥ 8 weeks of therapy)\n* No endoscopically diagnosed GERD\\*\\*\\*\n* No indication for a PPI-therapy according to guidelines.\n\nExamples for guideline recommendations for a PPI-therapy:\n\n* moderate - severe forms of reflux esophagitis\n* gastric ulcer, duodenal ulcer\n* Helicobacter pylori eradication\n* moderate\u002Fsevere forms of GERD - Los Angeles (LA) grade C\u002FD esophagitis\n* Zollinger-Ellison-Syndrome\n\nNo Talcid® contraindications or warnings as:\n\n* pregnancy and lactation\n* severe renal impairment\n* hypophosphatemia\n* existing myasthenia gravis\n* impaired renal function\n* Alzheimer's disease or other forms of dementia\n* patients under low-phosphate diet\n* hypersensitivity to the ingredients of Talcid®\n\n  * Subjects who voluntarily agree to use Talcid® Chewable Tablets for relief of acid-related symptoms due to acid-rebound\n  * Decision to initiate on-demand treatment of acid-related symptoms due to acid-rebound with Talcid® was made as per investigator's routine recommendation practice and by the subject\n  * Subject purchases Talcid® for her\u002Fhis own use\n  * Signed informed consent\n  * No participation in an investigational program with interventions outside of routine clinical practice\n  * No contraindications according to the local marketing authorization\n\n    \\* Warning signals:\n  * Age \\> 60 (with one additional warning signal)\n  * Previous history or family history of ulcers\n  * Helicobacter pylori positive status \\*\\* Polymedication: defined as at least five medicinal products at the same time for a continuous therapy \\*\\*\\* Endoscopy: LA grade C\u002F D esophagitis, Barrett esophagus, peptic stricture; pH- Impedance measurement: acid exposure \\> 6%\n\nExclusion Criteria: not applicable",{"count":107,"type":21},167,"OBSERVATIONAL","This observational study aims to explore the effectiveness of hydrotalcite, marketed as Talcid, in alleviating acid-related symptoms that occur due to an acid rebound after discontinuing a non-\u002Fno-longer-indicated long-term proton pump inhibitor (PPI) therapy. PPIs are commonly prescribed to reduce stomach acid to alleviate symptoms such as heartburn and for the treatment of, for example, duodenal and stomach ulcers. Discontinuation after prolonged use can lead to a rebound effect where dyspeptic complaints such as heartburn occur once the medication is stopped. This study is conducted in Germany and involves adult participants who have stopped using non-\u002Fno-longer-indicated PPIs and are experiencing these rebound symptoms.\n\nHydrotalcite is recommended by physicians as an on-demand treatment for managing acid-related symptoms. The study seeks to gather real-world evidence on its effectiveness, consumer experience, and acceptance to support claims about its use to relieve acid related symptoms due to an acid rebound. Participants will use hydrotalcite as needed (on demand when symptoms occur) over a four-week period, and will record information about symptom relief, the time it takes for relief to occur, and overall satisfaction with the treatment. Additionally, their doctors rate the suitability, tolerability, and effectiveness of the treatment.\n\nThe primary objective of the study is to assess the effectiveness of hydrotalcite by the number and percentage of patients not having used PPIs during the study period. Secondary objectives include evaluating relief from specific symptoms (heartburn, reflux, epigastric pain, feeling of fullness, and nausea, as well as improvements in quality of life due to hydrotalcite treatment. The study will also assess participants' satisfaction with hydrotalcite as an on-demand treatment and its suitability for managing these symptoms.\n\nParticipants will be adults aged 18 and older who have discontinued a long-term PPI therapy (≥8 weeks) for which there is no current indication according to indication and guidelines and who are experiencing acid rebound symptoms after stopping the PPI therapy. The study will exclude individuals with endoscopically diagnosed gastroesophageal reflux disease (GERD) (LA grade C\u002F D esophagitis) or those with hydrotalcite contraindications or warnings, such as pregnancy, severe renal impairment, or allergies to its ingredients.\n\nData will be collected through standardized questionnaires completed by participants after they consent to join the study. The study aims to enroll approximately 167 participants, anticipating a 40% drop-out rate, to ensure around 100 completed questionnaires. Statistical analyses will be exploratory and descriptive, focusing on categorical and continuous variables.\n\nThe study is designed to be observational, meaning there will be no direct intervention or randomization of participants. Instead, it will collect primary data directly from participants and investigators across approximately twenty sites in Germany. The results will provide valuable insights into the effectiveness of hydrotalcite in managing acid rebound symptoms and may inform future treatment recommendations for participants discontinuing long-term PPI therapy.",[28],[112,113,114,115,116,117,118],"Heartburn,","Gastroesophageal Reflux,","Nausea,","Epigastric Pain,","Feeling of Fullness,","Acid-related Symptoms,","Acid Rebound","2026-05-04",{"date":121,"type":33},"2026-05-05",{"date":123,"type":33},"2025-11-18",{"date":125,"type":21},"2026-10-31",{"name":127,"class":128},"Bayer","INDUSTRY",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":98},"100416202","compassionate-use-of-domperidone-for-refractory-gastroparesis-100416202","NCT04699591","Compassionate Use of Domperidone for Refractory Gastroparesis","Inclusion Criteria:\n\n1. Male or female\n2. Age 12 - 21\n3. Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.\n4. Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.\n5. Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:\n\n   * increased prolactin levels\n   * extrapyramidal side effects\n   * breast changes\n   * Cardiac arrhythmias including QT prolongation\n   * There is a potential for increased risk of adverse events with the drugs and herbal supplements listed in the addendum (See Addendum on pages 24 and 25)\n   * The coordinator\u002Finvestigator will have a discussion with the family about the use of any of the medications and herbal supplements listed in the addendum to make sure they understand the increased risk of their use and the need to contact the investigators prior to using any of the listed medications and herbal supplements.\n\nExclusion Criteria:\n\n1. History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.\n2. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged Tc (QTc\\> 450 milliseconds for males, QTc\\>470 milliseconds for females).\n3. Clinically significant electrolyte disorders.\n4. Gastrointestinal hemorrhage or obstruction\n5. Presence of a prolactinoma (prolactin-releasing pituitary tumor).\n6. Pregnant or breast feeding female\n7. Known allergy to domperidone","12 Years","21 Years",{"count":138,"type":21},20,[24],"The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.",[56,28,142],"Gastroparesis",[144,145],"reflux","acid reflux","2026-03-20",{"date":148,"type":33},"2026-03-24",{"date":150,"type":4},"2013-04",{"date":152,"type":21},"2035-12",{"name":154,"class":40},"Jose Cocjin",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":98},"100492841","external-ues-band-shaker-pressure-band-and-gerd-100492841","NCT05697393","External UES Band (Shaker Pressure Band) and GERD","External Upper Esophageal Sphincter Band (Shaker Pressure Band) and Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* The patient must be 18 years of age or older.\n* Patients with gastroesophageal reflux disease (GERD) who has ear, nose, and throat symptoms, chronic cough, choking, or regurgitation (food coming back up into the throat).\n* The patient has been diagnosed with GERD with extra-esophageal symptoms, esophagitis, hiatal hernia, achalasia, or diffuse esophageal spasm.\n* The patient must not be pregnant or lactating.\n\nExclusion Criteria:\n\n* The patient cannot be younger than 18 years of age or older than 85.\n* The patient cannot have sleep apnea or be on CPAP\n* Patient cannot have previous head or neck surgery or radiation.\n* Patient cannot have carotid artery disease, thyroid disease or history of cerebral vascular disease.\n* Patients with an inability to tolerate nasal intubation.\n* Patients with significant bleeding disorders for whom nasal intubation has been deemed contraindicated\n* Patients with a known esophageal obstruction prevent passage of the manometry probe.","85 Years",{"count":164,"type":21},350,[24],"This protocol is a study to assess the efficacy of an external upper esophageal band to decrease subjective nighttime symptoms related to esophageal reflux into the pharynx.",[28],"2026-03-05",{"date":170,"type":33},"2026-03-09",{"date":172,"type":33},"2011-01-25",{"date":174,"type":21},"2026-11-30",{"name":176,"class":40},"Medical College of Wisconsin",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":74},"100394112","post-sleeve-gastrectomy-gastroesophageal-reflux-disease-prediction-100394112","NCT04411823","Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction","Prediction of Post-laparoscopic Sleeve Gastrectomy Gastroesophageal Reflux Disease With an Endolumenal Functional Lumen Imaging Probe (EndoFLIP)","Inclusion Criteria:\n\n* Adult patients \\> 18 years\n* BMI 30 or greater kg\u002Fm2\n* Participants can give a consent to the procedure\n* Participants have no contraindications to LSG (gastric ulceration)\n\nExclusion Criteria:\n\n* Participants who have LA grade C or D esophagitis, Barrett mucosa or peptic stricture.\n* Patients who have evidence of a major motility abnormality defined by the Chicago classification version 3.0 (achalasia, absent contractility, esophagogastric junction outflow obstruction, distal esophageal spasm, or hypertensive peristalsis)\n* Patients with hiatal hernia \\> 3 cm\n* Patients with previous esophageal or stomach surgery",{"count":185,"type":21},200,[24],"Researchers are trying to identify predictors for gastroesophageal reflux disease after sleeve gastrectomy.",[28,189,190],"Sleeve Gastrectomy","Bariatric Surgery Complication",[28,192],"Sleeve gastrectomy","2026-03-03",{"date":168,"type":33},{"date":196,"type":33},"2021-02-01",{"date":198,"type":21},"2028-10",{"name":200,"class":40},"Mayo Clinic",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":210,"briefSummary":211,"conditions":212,"keywords":214,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":98},"100514259","a-study-of-breath-testing-for-small-intestinal-bacterial-overgrowth-100514259","NCT05976165","A Study of Breath Testing for Small Intestinal Bacterial Overgrowth","Breath Testing for Small Intestinal Bacterial Overgrowth in Patients Treated With Proton Pump Inhibitors","Inclusion criteria:\n\n* Predominant symptoms of gastroesophageal reflux disease including heartburn, regurgitation\n* Subjects must be able to give appropriate informed consent\n\nExclusion criteria:\n\n* Prior diagnosis of SIBO\n* Use of PPIs or H2R-anatagonstists in the prior 3 months\n* Major concomitant illness (renal, hepatic, rheumatologic or cardiovascular disease, or malignancy)\n* Antibiotic therapy within one month\n* Prior gastrointestinal surgery including esophageal, gastric, and small or large bowel surgery\n* Previously diagnosed irritable bowel syndrome or inflammatory bowel disease\n* Individuals who are pregnant or breast feeding\n* Patients with plans to become pregnant\n* Inability to take PPIs, including allergy\u002Fsensitivity",{"count":209,"type":21},50,[24],"Researchers hope to determine how often small intestinal bacterial overgrowth occurs after taking proton pump inhibitors.",[28,213,58],"Regurgitation",[215],"Proton pump inhibitor","2026-02-10",{"date":218,"type":33},"2026-02-12",{"date":220,"type":33},"2023-11-17",{"date":222,"type":21},"2027-01-31",{"name":200,"class":40},{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":258},"100535750","phase-4-treatment-of-gastroesophageal-reflux-disease-in-infants-100535750","NCT06255886","Treatment of Gastroesophageal Reflux Disease in Infants","Treatment of Gastroesophageal Reflux Disease in Infants- a Randomized Controlled Trial","Inclusion Criteria:\n\n* Infants diagnosed with gastroesophageal reflux disease (GERD)\n* Age \\\u003C 1 year at the time of referral\n* Age \\>1 month at start of treatment\n* At least 3 reflux episodes\u002Fdaily in average\n* At least one of following troublesome symptoms are present: Crying of unknown reason, discomfort\u002Firritability, problems gaining weight\u002F weightloss, rejects the breast or bottle, apnea, back-arching.\n\nExclusion Criteria:\n\n* Children with diagnosed or suspected syndrome \u002Fgenetic disorder\n* Congenital malformations (minor deformities are excepted)\n* Abdominal surgery\n* Metabolic disease\n* Treatment with proton pump inhibitor within the last week\n* Allergy for proton pump inhibitors\n* Allergy for cow milk protein\n* Infants on Cow's milk free diet","1 Year",{"count":52,"type":21},[234],"PHASE4","Gastroesophageal reflux disease in infants is not fully understood. Infants are prescribed medical treatments that may not be effective or that contribute to adverse side effects and lead to concerns and expenses for the parents and healthcare system. Current guidelines recommend cow-milk-protein free diet as a first-line treatment, but these recommendations are based on weak evidence. This study investigate the efficacy of a cow-milk-protein free diet compared to treatment with a proton pump inhibitor (omeprazole)",[28,237],"Infant, Newborn, Diseases",[239,240,56,241,242,243,244,245,246,215,247,248],"Reflux","Infants","GER","GORD","GOR","Cow milk protein","Bovine milk protein","CMP","PPI","Omeprazole","2025-11-17",{"date":251,"type":33},"2025-11-20",{"date":253,"type":33},"2025-10-27",{"date":255,"type":21},"2026-12-26",{"name":257,"class":40},"Odense University Hospital",3,{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":265,"sex":16,"minAge":266,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":286},"100568928","multi-site-detection-of-barretts-esophagus-in-patients-without-chronic-gerd-symptoms-100568928","NCT06687603","Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms","Inclusion Criteria:\n\nPatients undergoing screening colonoscopy are an accessible cohort for BE screening and are also a reasonable representation of the general population. Permission will be obtained from colonoscopy physicians for researchers to contact and recruit patients for this study. Patients without GERD, who are at risk for BE, and who have not had a prior EGD, will be recruited prior to or at the time of scheduled colonoscopy.(9) Those eligible will be:\n\n* Adults who have not had prior EGD within past ten years, and are able to provide informed consent, and who have:\n* No known coagulopathy, no known esophageal varices, not on chronic anticoagulation therapy, and have:\n* No significant dysphagia or odynophagia; but who do have:\n* Absence of GERD (absence of weekly heartburn or regurgitation, not on medications for GERD), and are:\n* Adults \\> age 50, who also have two or more added risk factors for BE from the set of: central obesity (waist size \\> 35 inches for women and \\> 40 inches for men), current smoker or smoking history \\> 10 pack years, white race, male sex, confirmed history of BE\u002FEAC in at least two family members, with one a first degree relative. While BE is most highly prevalent in white males, a black female over age 50 with obesity and a positive smoking history would also be at increased BE risk and would equally meet eligibility criteria.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n* Subjects must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* History of prior EGD procedure in past ten years\n* Inability to provide written informed consent\n* History of weekly of more frequent heartburn or regurgitation for five or more years\n* On anti-coagulant drug(s) that cannot be temporarily discontinued or coagulopathy with INR \\> 1.5\n* Known history of esophageal varices or esophageal stricture\n* Any contraindication, as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and\u002For having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and\u002For esophageal ulceration\n* History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills\n* Oropharyngeal tumor\n* History of esophageal or gastric surgery, with exception of uncomplicated surgical fundoplication procedure",true,"50 Years",{"count":268,"type":21},800,[24],"The goal of this clinical trial is to develop a method to detect Barrett's esophagus in individuals with a new office based diagnostic test. Barrett's esophagus is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged by acid reflux. The main question it aims to answer is: Can this approach demonstrate efficacy for screening of Barrett's esophagus?\n\nParticipants will:\n\n* Participate in a questionnaire.\n* Undergo a capsule balloon test, called EsoCheck.\n* Have their EsoCheck sample sent to the laboratory for an EsoGuard test, which is used to detect Barrett's esophagus.\n* Participants will undergo upper endoscopy as part of standard of care.",[272,28,273],"Barrett Esophagus","Esophageal Adenocarcinoma",[275,276],"Esophagus","Non-endoscopic","2025-11-12",{"date":279,"type":33},"2025-11-13",{"date":281,"type":33},"2025-03-10",{"date":283,"type":21},"2029-09-27",{"name":285,"class":40},"Case Comprehensive Cancer Center",5,{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":295,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":98},"100518475","prevalence-and-natural-history-of-functional-gastrointestinal-disorders-among-at-risk-infants-100518475","NCT06031025","Prevalence and Natural History of Functional Gastrointestinal Disorders Among At-risk Infants.","Prospective Assessment of the Prevalence and Natural History of Gastroesophageal Reflux and Functional Gastro-intestinal Disorders Among At-risk Infants","FUSID","Inclusion Criteria:\n\n* infants with gestational age at birth \\\u003C 31 weeks\n* infants with gestational age at birth \\\u003C 37 weeks and major respiratory or neurologic morbidity\n* infants with history of perinatal asphyxia\n\nExclusion Criteria:\n\n* lack of informed consent\n* diagnosis of congenital or other major gastrointestinal disease (i.e. inflammatory bowel disease, cancer)","3 Months","24 Months",{"count":298,"type":21},71,"The goal of this observational study is to learn about the prevalence and characteristics of functional gastrointestinal disorders (FGID) in at risk infants (former preterm infants and those with birth asphyxia) during the first 2 years of life. The main questions it aims to answer are:\n\n* evaluate the prevalence of symptoms related to gastro-esophageal reflux (GER), of functional gastrointestinal disorders during the first 2 years of life\n* describe growth parameters during follow-up up to the corrected age of 2 years Participants will be assessed clinically and with a structured questionnaire based on the Rome IV criteria to describe FGID.",[301,28,302,303,304,305,306],"Functional Gastrointestinal Disorders","Constipation - Functional","Diarrhea","Dyschezia","Colic, Infantile","Vomiting; Cyclical",{"date":308,"type":33},"2025-03-11",{"date":310,"type":33},"2022-05-20",{"date":312,"type":21},"2025-09-30",{"name":314,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":321,"enrollmentInfo":322,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":98},"100542202","role-of-mucosal-impedance-measurement-for-the-diagnosis-of-gastroesophageal-reflux-disease-100542202","NCT06339801","Role of Mucosal Impedance Measurement for the Diagnosis of Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* Patients \\>18 years presenting symptoms of GERD that have not adequately responded to proton pump inhibitors (PPIs) treatment after 8 weeks and have undergone upper gastrointestinal endoscopy (UGIE) without erosive esophagitis.\n\nPatients with a broad spectrum of severity, assessed through the GERDq score, will be included\n\nExclusion Criteria:\n\n* ● Pregnancy or lactation\n\n  * Esophageal disorders (esophageal motor disorders, eosinophilic esophagitis, neoplastic diseases)\n  * Uncontrolled systemic diseases (diabetes mellitus, hypo- or hyperthyroidism, cancer, etc.)\n  * Lack of informed consent\n  * Severe psychiatric disorders","65 Years",{"count":83,"type":21},"Existing current tests for diagnosing GERD are suboptimal because they lack adequate sensitivity or specificity. Upper gastrointestinal endoscopy is highly specific for diagnosing GERD, particularly when erosive esophagitis is present (Los Angeles Classification B, C, or D). Nevertheless, its sensitivity is limited, as this scenario is only present in 30% of cases. Most patients will exhibit normal endoscopic findings, indicating Non-Erosive Reflux Disease (NERD). The 24-hour impedance-pH monitoring (MII) is currently considered the gold standard. However, its main limitation is that it can only measure reflux activity over a 24-hour period, in addition to the discomfort caused by the catheter. 6-8 It is noteworthy that 50% of patients with NERD will have pathological reflux, and the other 50% will have a sensory disorder. The importance of making an accurate diagnosis lies in the treatment, which varies in each case.11 Recently, a minimally invasive device was developed and validated in the USA to assess changes in esophageal mucosal impedance. This serves as a tool for evaluating tissue changes associated with chronic reflux. However, this device has recently undergone improvements. This new technology has not been tested yet for GERD diagnosis. The primary benefit would be the ability to diagnose GERD in symptomatic patients with NERD during the initial endoscopy conducted under sedation.\n\nObjectives\n\nThe Main objectives of this study are to:\n\n1. Evaluate the diagnostic performance of mucosal impedance measurement.\n2. Investigate the mucosal impedance pattern in patients with and without GERD.\n\nSecondary objectives:\n\n1. Evaluate the correlation between the global mucosal impedance measurement vs the first 3cm measurement\n2. Evaluate the best probability score to distinguish between GERD and non-GERD Design Prospective, cross-sectional, and analytical study Study Design and Procedures The study will be conducted in the Gastroenterology Department of the Hospital de Clínicas José de San Martin, University of Buenos Aires, Argentina. Following a 4-week screening period during which a proton pump inhibitor (PPI) washout will be performed, and baseline measurements will be taken, all patients will undergo upper gastrointestinal endoscopy with mucosal impedance measurement and 24-hour impedance\u002FpH monitoring.",[28],[326,327],"gastroesophageal reflux","mucosal impedance","2025-01-01",{"date":330,"type":33},"2025-01-03",{"date":332,"type":33},"2024-12-12",{"date":334,"type":21},"2026-08-01",{"name":336,"class":40},"Hospital de Clinicas José de San Martín",{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":343,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":345,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":347,"conditions":348,"keywords":351,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":98},"100101977","barretts-esophagus-related-neoplasia-bern-project-100101977","NCT00590239","Barrett's Esophagus Related Neoplasia (BERN) Project","Endoscopic Detection of Early Neoplasia in Patients With Barrett's Esophagus","BERN","Inclusion Criteria:\n\n* 18-80 years\n* Patients must be able to provide written informed consent\n* Patients referred for endoscopy for screening\u002Fsurveillance of BE or for endoscopic treatment of BE with early mucosal neoplasia\n\nExclusion Criteria:\n\n* Current use of aspirin, non-steroidal anti-inflammatory agents(NSAIDs),or chronic anticoagulants that cannot be discontinued prior to the procedure.\n* Inability to provide written informed consent\n* Significant thrombocytopenia or coagulopathy\n* Any significant co-morbid condition that would prevent the safe administration of conscious sedation",{"count":346,"type":21},150,"* The use of high resolution endoscopy (HRE), narrow band imaging (NBI) and chromoendoscopy increases the detection rates of Barrett's esophagus (BE) and early neoplasia.\n* Endoscopic mucosal resection (EMR) will improve the accuracy for detection of dysplasia\u002Fearly neoplasia.\n\nSpecific Aim 1 - To create a video-atlas of non-dysplastic and dysplastic\u002Fearly neoplastic lesions in patients with BE. This will be used for training purposes and to assess learning curve associated with these new technologies.\n\nSpecific Aim 2 - To create a standardized classification system for the mucosal and vascular patterns observed in patients with BE.\n\nSpecific Aim 3 - To determine the interobserver agreement using the video-atlas for the mucosal and vascular patterns classification agreed upon.\n\nSpecific Aim 4 - To determine the endoscopic detection rate of esophageal cancer or precancerous lesions removed during endoscopy.\n\nSpecific Aim 5 - To determine the pathologic and clinical outcomes of patients undergoing EMR\u002Fablation; including morbidity, mortality and complications of the procedure.\n\nResults to date (June 2008) : this study is active and open to enrollment. Currently 26 patients have enrolled in this study at the Kansas City VA medical center. In order to participate, patients must be eligible for care at the KCVA hospital.",[349,350,28],"Barrett's Esophagus","Neoplasms",[349,352,353,354,355],"Neoplasia","Endoscopic mucosal resection","High resolution endoscopy","Chromoendoscopy","2024-11-20",{"date":358,"type":33},"2024-11-22",{"date":360,"type":33},"2007-05-15",{"date":362,"type":21},"2026-12-30",{"name":364,"class":40},"Midwest Biomedical Research Foundation",{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":4,"eligibilityCriteria":371,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":22,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":41},"100493376","sleeve-pex-a-randomized-trial-to-reduce-reflux-after-sleeve-gastrectomy-100493376","NCT05704348","Sleeve-pex: A Randomized Trial to Reduce Reflux After Sleeve Gastrectomy","A Clinical Intervention Study Exploring Gastropexy as a Measure to Reduce Gastro-oesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy","Inclusion Criteria:\n\n* Patients planned for bariatric surgery with primary LSG\n\nExclusion Criteria:\n\n* Age below 18 yrs\n* Use of ARM for other reasons than reflux\n* Previous antireflux surgery\n* Inability to comprehend and respon to patient related outcome (PRO) questionnaire",{"count":373,"type":21},550,[24],"The goal of this clinical trial is to test gastropexy as a measure to reduce reflux in morbidly obese patients being submitted to sleeve gastrectomy. The main questions it aims to answer are:\n\nDoes gastropexy reduce reflux symptoms? Does gastropexy reduce objective evidence of reflux? Participants will be randomized to gastropexy or no gastropexy, and researchers will compare these groups to see if reflux (symptoms \u002F objective evidence of) is different in the two groups.",[28],"2024-10-28",{"date":379,"type":33},"2024-10-30",{"date":381,"type":33},"2023-09-04",{"date":383,"type":21},"2030-12",{"name":385,"class":40},"Helse Forde",{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":22,"phases":395,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":98},"100508458","developing-and-testing-mobile-health-question-prompt-list-in-gastroesophageal-reflux-disease-100508458","NCT05900687","Developing and Testing Mobile Health Question Prompt List in Gastroesophageal Reflux Disease","Developing, Refining, and Testing a Mobile Health Question Prompt List in Gastroesophageal Reflux Disease","Inclusion Criteria:\n\n* clinical diagnosis of GERD\n* GerdQ score of \\>=8\n* documented PPI use for GERD\n* internet access at home or computer\u002Fmobile device\n* ability to provide written or e-consent.\n\nExclusion Criteria:\n\n* Established diagnosis that mimic GERD symptoms (e.g. achalasia by prior esophageal manometry)\n* non-English speaking patients","100 Years",{"count":346,"type":21},[24],"More than 40% of patients with gastroesophageal reflux disease (GERD) experience uncontrolled, chronic symptoms. This proposal aims to improve symptom control for patients with GERD, by developing a mobile health (mHealth) Question Prompt List (QPL) intervention that helps patient ask questions with his\u002Fher physician about GERD. The first aim is to gather feedback about daily challenges of living with GERD. The second aim is to gather feedback on the prototype app. The third (primary) aim of this project is to develop the mHealth application and measure differences in patient activation when used compared to standard of care.",[28,398],"Patient Activation","2023-05-31",{"date":401,"type":33},"2023-06-12",{"date":403,"type":21},"2023-07-01",{"date":405,"type":21},"2028-06-01",{"name":407,"class":40},"Stanford University",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":16,"minAge":136,"maxAge":321,"enrollmentInfo":416,"targetDuration":4,"studyType":22,"phases":417,"briefSummary":418,"conditions":419,"keywords":423,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":428,"lastUpdatePostDateStruct":429,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":434,"locationsCount":74},"100464685","crural-repair-during-laparoscopic-sleeve-gastrectomy-in-patients-with-a-lax-gastroesophageal-junction-100464685","NCT05330910","Crural Repair During Laparoscopic Sleeve Gastrectomy in Patients With a Lax Gastroesophageal Junction","A Randomized Controlled Trial Evaluating PAtients With Lax Gastroesophageal Junction to Initial Sleeve Gastrectomy With or Without Concomitant Crural Repair (REPAIR)","REPAIR","Inclusion Criteria:\n\n* 21-65 years old\n* Able to provide informed consent\n* Hill's grade III gastroesophageal junction on preoperative endoscopy\n* Opted to undergo laparoscopic sleeve gastrectomy as their bariatric procedure\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent\n* Contraindications to laparoscopic sleeve gastrectomy\n* Opted not to undergo laparoscopic sleeve gastrectomy\n* Had previous upper gastrointestinal surgery\n* Had documented erosive esophagitis on preoperative endoscopy\n* Had Hill's grade I, II or IV gastroesophageal junction on preoperative endoscopy",{"count":52,"type":21},[24],"Background:\n\nLaparoscopic sleeve gastrectomy (LSG) is one of the commonest bariatric procedures. However, it is associated with postoperative gastroesophageal reflux disease (GERD) and erosive esophagitis (EE). The investigators' preliminary study suggests that the incidence of postoperative GERD and EE appears to be correlated with the preoperative presence of a lax gastroesophageal flap valve and hiatal hernia.\n\nHypothesis\u002F Aim:\n\nTo investigate the impact of a concomitant hiatal hernia repair with LSG on the incidence of postoperative EE.\n\nSignificance:\n\nFor patients with pre-existing EE, most surgeons will recommend a laparoscopic Roux-en-Y gastric bypass (LRYGB) as their primary bariatric procedure. However, compared to LSG, LRYGB is a technically more demanding procedure with increased morbidity and long term nutritional deficiencies. For asymptomatic patients at risk of postoperative EE due to presence of a hiatal hernia, there is still no consensus on the most appropriate bariatric surgical option. A LSG with a concomitant hiatal hernia repair, if shown to reduce EE postoperatively, may help to expand the pool of patients suitable for LSG in the future.\n\nMethods:\n\nA two center, double-blinded, randomized controlled trial of all patients, undergoing LSG with a preoperative diagnosis of a Hill's grade III gastroesophageal junction, will be randomized to having a concomitant hiatal hernia repair (experimental arm) versus just LSG alone (control arm). Primary outcome measures include 1-year postoperative EE on endoscopy. Secondary outcome measures include postoperative morbidity, blood loss, quality of life and GERD symptoms at 1-year postoperatively.",[420,421,422,28],"Obesity","Bariatric Surgery Candidate","Esophagus Injury",[420,424,425,426,427],"Bariatric Surgery","Esophagitis","Gastroesophageal reflux disease","Laparoscopic sleeve gastrectomy","2022-04-10",{"date":430,"type":33},"2022-04-15",{"date":432,"type":33},"2022-04-01",{"date":71,"type":21},{"name":435,"class":40},"Sengkang General Hospital"]